Imidazolyl derivatives as corticotropin releasing factor...

Details Imidazolyl derivatives as corticotropin releasing factor... Imidazolyl derivatives as corticotropin releasing factor...

2005-05-03

2005-05-03

Vollano, Jean F. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S267000, C514S259300, C514S293000, C514S303000, C514S393000, C544S281000, C548S303100, C548S250000, C548S258000, C548S262400, C546S082000, C546S084000, C546S118000

Reexamination Certificate

active

06888004

ABSTRACT:
The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”)useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

REFERENCES:
patent: 6414161 (2002-07-01), Frutos et al.
patent: 6433183 (2002-08-01), Frutos et al.
patent: 6437148 (2002-08-01), Frutos et al.
patent: 6441183 (2002-08-01), Frutos et al.
patent: 6458986 (2002-10-01), Frutos et al.
patent: 6492408 (2002-12-01), Wu et al.
patent: 0 778 277 (1997-06-01), None
patent: 0 812 831 (1997-12-01), None
patent: 0902029 (1999-03-01), None
patent: WO 9835967 (1998-08-01), None
patent: WO 9901454 (1999-01-01), None
patent: WO 9910350 (1999-03-01), None
patent: WO 9967247 (1999-12-01), None
patent: WO 0001675 (2000-01-01), None
patent: WO 0001697 (2000-01-01), None
patent: WO 0039127 (2000-07-01), None
patent: WO 0059907 (2000-10-01), None
patent: WO 0059908 (2000-10-01), None
Dunn, et al., “Physiological and behavioral response to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?”, Brain Research Reviews, 15, 1990, pp. 71-100.
Gulyas, et al., “Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor,” Prac. Natl. Acad. Sci. USA, 92, 1995, pp. 10575-10579.
McCarthy, et al., “Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications,” Current Pharmaceutical Design, 5, 1999, pp. 289-315.
Holsboer, “The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety,” Journal of Psychiatric Research, 33, 1999, pp. 181-214.
Banki, et al., “CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse,” European Neuropsychopharmacology, 2, 1992, pp. 107-113.
Zobel, et al., “Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression, the first 20 patients treated,” Journal of Psychiatric Research, 34, 2000, pp. 171-181.
Webster, et al., “Corticotropin-Releasing Hormone and Inflammation,” Annals New York Academy of Sciences, 840, 1998, pp. 21-62.
Gilligan, et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents,” Journal of Medicinal Chemistry, 43, 9, 2000, pp. 1641-1660.
McCarthy, et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents, ” Annual Reports in Medicinal Chemistry, 34, 1999, pp. 11-20.

Affiliated with

Also associated with

Rating

Imidazolyl derivatives as corticotropin releasing factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazolyl derivatives as corticotropin releasing factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolyl derivatives as corticotropin releasing factor... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3418945